Paradigm Medical Industries Plans to Begin Clinical Work to Upgrade Its CPT Code for Its Blood Flow Analyzer From an Investigati
27 May 2009 - 3:47AM
Marketwired
Paradigm Medical Industries, Inc. (OTCBB: PDMI) announced today
that the Company plans to begin the important process of upgrading
its CPT code (0189T) for its Blood Flow Analyzer from the American
Medical Association from an investigational level (Class III) to
one that will enable public and private medical centers to be
reimbursed by their regional medical insurance companies for
testing patients using the Blood Flow Analyzer. The Blood Flow
Analyzer is used to detect glaucoma and aid in managing the
disease.
Current Procedural Terminology (CPT) coding is a standard,
universal code that is applied to medical procedures and services
for the purpose of patient records. CPT is to provide a uniform
language that accurately describes medical, surgical, and
diagnostic services, and thereby serves as an effective means for
reliable nationwide communication among physicians, and other
healthcare providers, patients and third parties. Receiving a
reimbursable CPT Code will be an important step towards the Blood
Flow Analyzer's acceptance as a standard diagnostic instrument in
early detection of glaucoma in patients.
"We are confident that by taking the next important clinical
steps to complete the process of upgrading this CPT code to a
reimbursable level, both public and private payers will be
encouraged to reimburse physicians for utilizing the Blood Flow
Analyzer," said Paradigm Medical President Stephen Davis. "Moving
the Blood Flow Analyzer from an investigational level to an
acceptable diagnostic procedure will benefit patients and
physicians alike by offering earlier glaucoma diagnosis and
treatment."
About Paradigm Medical Industries, Inc.
Headquartered in Salt Lake City, UT, Paradigm Medical
Industries, Inc. is a medical device company that develops,
manufactures and distributes cutting edge, new innovative products
in the diagnostic ultrasound and early glaucoma detection markets.
Paradigm has the only patented technology utilizing photon laser
for cataract removal. The Company is poised to capture a niche
market within the Glaucoma and ultrasound microscopy fields.
Paradigm Medical Industries markets its products to
ophthalmologists, optometrists, universities, and clinics
throughout the United States, as well as internationally.
For more information, please visit: www.paradigm-medical.com
This press release contains statements that, if not verifiable
historic fact, may be viewed as forward-looking statements that
could predict future events and outcomes with respect to Paradigm
and its business. The predictions embodied in these statements will
involve risk and uncertainties and, accordingly, actual results may
differ significantly from the results discussed or implied in such
forward-looking statements.
Contact: Paradigm Medical Industries, Inc. Stephen Davis
President 801-977-8970 www.paradigm-medical.com
Paradigm Medical Industr... (CE) (USOTC:PDMI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Paradigm Medical Industr... (CE) (USOTC:PDMI)
Historical Stock Chart
From Dec 2023 to Dec 2024